DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2022-06-01

Last Posted Date: 2024-07-15

Lead Sponsor: Pfizer

Target Recruit Count: 688

Registration Number: NCT05399329

Locations: 🇯🇵
Japan Community Health care Organization Kurume General Hospital, Kurume-city, Fukuoka, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan

and more 17 locations

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Rimegepant 25 MG
Drug: Rimegepant 75 MG
Drug: Placebo

First Posted Date: 2022-06-01

Last Posted Date: 2025-03-07

Lead Sponsor: Pfizer

Target Recruit Count: 897

Registration Number: NCT05399459

Locations: 🇯🇵
Narikawa Neurological Clinic, Izumi-ku, Miyagi, Japan
🇯🇵
Tokyo Headache Clinic, Shibuya-Ku, Tokyo, Japan
🇯🇵
Fukuuchi Pain Clinic, Shinjuku-ku, Tokyo, Japan

and more 47 locations

Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2022-06-01

Last Posted Date: 2025-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 496

Registration Number: NCT05399485

Locations: 🇯🇵
Medical Corporation Seikokai Takanoko Hospital, Matsuyama-shi, Ehime, Japan
🇯🇵
Jinnouchi Neurosurgical Clinic, Kasuga-shi, Fukuoka, Japan
🇯🇵
Ikeda Neurosurgical Clinic, Kasuga-shi, Fukuoka, Japan

and more 41 locations

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: avelumab
Drug: axitinib

First Posted Date: 2022-05-27

Last Posted Date: 2023-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 130

Registration Number: NCT05394493

Locations: 🇬🇧
Pfizer Ltd, Sandwich, Kent, United Kingdom

A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

Recruiting

Conditions: Dermatitis, Atopic

First Posted Date: 2022-05-25

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 1100

Registration Number: NCT05391061

Locations: 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of

A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: CIBINQO

First Posted Date: 2022-05-24

Last Posted Date: 2025-05-15

Lead Sponsor: Pfizer

Target Recruit Count: 1200

Registration Number: NCT05387980

Locations: 🇯🇵
Pfizer Local Country Office, Tokyo, Japan

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

Phase 1

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: nirmatrelvir
Drug: ritonavir

First Posted Date: 2022-05-23

Last Posted Date: 2025-05-04

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT05386472

Locations: 🇺🇸
University of Alabama at Birmingham/Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸
Beautiful Minds Clinical Research Center, Cutler Bay, Florida, United States
🇺🇸
Omega Research Debary, DeBary, Florida, United States

and more 9 locations

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Phase 1

Active, not recruiting

Conditions: Metastatic HER2+ Advanced Breast Cancer
Breast Neoplasms
Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Colorectal Cancer

Interventions: Drug: Tucatinib

First Posted Date: 2022-05-19

Last Posted Date: 2025-03-20

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT05382364

Locations: 🇨🇳
Harbin Medical University Cancer Hospital-oncology of department ( Site 0010), Harbin, Heilongjiang, China
🇨🇳
Hunan Cancer Hospital-Digestion and Urology ( Site 0008), Changsha, Hunan, China
🇨🇳
Jilin Cancer Hospital-oncology department ( Site 0007), Changchun, Jilin, China

and more 2 locations

This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Inflectra

First Posted Date: 2022-05-17

Last Posted Date: 2024-04-12

Lead Sponsor: Pfizer

Target Recruit Count: 255

Registration Number: NCT05375942

Locations: 🇺🇸
Pfizer, Collegeville, Pennsylvania, United States

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Phase 2

Completed

Conditions: Plaque Psoriasis
Atopic Dermatitis

Interventions: Drug: PF-07038124 ointment 0.01%
Drug: PF-07038124 ointment 0.06%
Drug: PF-07038124 ointment 0.03%
Drug: Vehicle ointment

First Posted Date: 2022-05-17

Last Posted Date: 2024-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 263

Registration Number: NCT05375955

Locations: 🇺🇸
Texas Dermatology and Laser Specialists, San Antonio, Texas, United States
🇨🇦
Lynderm Research Inc., Markham, Ontario, Canada
🇺🇸
Renaissance Research and Medical Group, Cape Coral, Florida, United States

and more 33 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy